PT3818065T - Derivados fosfato e fosfonato de 7-amino-5-tio-tiazolo[4,5-d]pirimidinas e sua utilização no tratamento de condições associadas a níveis elevados de cx3cr1 e/ou de cx3cl1 - Google Patents

Derivados fosfato e fosfonato de 7-amino-5-tio-tiazolo[4,5-d]pirimidinas e sua utilização no tratamento de condições associadas a níveis elevados de cx3cr1 e/ou de cx3cl1

Info

Publication number
PT3818065T
PT3818065T PT197392343T PT19739234T PT3818065T PT 3818065 T PT3818065 T PT 3818065T PT 197392343 T PT197392343 T PT 197392343T PT 19739234 T PT19739234 T PT 19739234T PT 3818065 T PT3818065 T PT 3818065T
Authority
PT
Portugal
Prior art keywords
cx3cl1
cx3cr1
thiazolo
pyrimidines
thio
Prior art date
Application number
PT197392343T
Other languages
English (en)
Original Assignee
Kancera Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kancera Ab filed Critical Kancera Ab
Publication of PT3818065T publication Critical patent/PT3818065T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT197392343T 2018-07-06 2019-07-05 Derivados fosfato e fosfonato de 7-amino-5-tio-tiazolo[4,5-d]pirimidinas e sua utilização no tratamento de condições associadas a níveis elevados de cx3cr1 e/ou de cx3cl1 PT3818065T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1811169.0A GB201811169D0 (en) 2018-07-06 2018-07-06 New compounds

Publications (1)

Publication Number Publication Date
PT3818065T true PT3818065T (pt) 2023-05-30

Family

ID=63273083

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197392343T PT3818065T (pt) 2018-07-06 2019-07-05 Derivados fosfato e fosfonato de 7-amino-5-tio-tiazolo[4,5-d]pirimidinas e sua utilização no tratamento de condições associadas a níveis elevados de cx3cr1 e/ou de cx3cl1

Country Status (23)

Country Link
US (2) US12060380B2 (pt)
EP (1) EP3818065B1 (pt)
JP (1) JP7506653B2 (pt)
KR (1) KR20210032403A (pt)
CN (1) CN112867725B (pt)
AU (1) AU2019297572A1 (pt)
CA (1) CA3105566A1 (pt)
CY (1) CY1126070T1 (pt)
DK (1) DK3818065T3 (pt)
ES (1) ES2945561T3 (pt)
FI (1) FI3818065T3 (pt)
GB (1) GB201811169D0 (pt)
HR (1) HRP20230532T1 (pt)
HU (1) HUE062011T2 (pt)
IL (1) IL279818B2 (pt)
LT (1) LT3818065T (pt)
MX (1) MX2021000011A (pt)
PL (1) PL3818065T3 (pt)
PT (1) PT3818065T (pt)
SG (1) SG11202100014RA (pt)
SI (1) SI3818065T1 (pt)
WO (1) WO2020008064A1 (pt)
ZA (1) ZA202100192B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201811169D0 (en) * 2018-07-06 2018-08-29 Kancera Ab New compounds
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0101082D0 (sv) * 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
ATE403428T1 (de) * 2003-06-27 2008-08-15 Pfizer Prod Inc Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
KR20060120014A (ko) 2003-10-07 2006-11-24 아스트라제네카 아베 케모킨, 특히 cx3cr1 수용체 길항제로서 유용한 신규한2-치환된 4-아미노-티아졸로[4,5-d]피리미딘
ATE417830T1 (de) 2004-11-02 2009-01-15 Pfizer Sulfonylbenzimidazolderivate
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
WO2008005555A1 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc. Modulators of toll-like receptor 7
AU2007300749B2 (en) * 2006-09-29 2011-08-25 Astrazeneca Ab Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3H)-amine derivatives and their use in therapy
UA95811C2 (en) * 2006-09-29 2011-09-12 Астразенека Аб 5,7-disubstituted [1,3]thiazolo [4,5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy
TW200820973A (en) * 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
TW200942549A (en) * 2007-12-17 2009-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
PL2254869T3 (pl) 2008-03-07 2017-10-31 Acraf Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40
AR071036A1 (es) 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
CN103118682A (zh) * 2010-04-30 2013-05-22 加利福尼亚大学校务委员会 合成tlr7激动剂的磷脂缀合物的用途
WO2013187978A1 (en) 2012-06-16 2013-12-19 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
US20180222922A1 (en) 2015-06-08 2018-08-09 The Johns Hopkins University Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1)
GB201811169D0 (en) * 2018-07-06 2018-08-29 Kancera Ab New compounds

Also Published As

Publication number Publication date
WO2020008064A1 (en) 2020-01-09
AU2019297572A1 (en) 2021-01-28
DK3818065T3 (da) 2023-05-15
FI3818065T3 (fi) 2023-06-13
IL279818A (en) 2021-03-01
JP2021530474A (ja) 2021-11-11
US12060380B2 (en) 2024-08-13
CY1126070T1 (el) 2023-11-15
SI3818065T1 (sl) 2023-08-31
US20210292349A1 (en) 2021-09-23
LT3818065T (lt) 2023-06-26
EP3818065A1 (en) 2021-05-12
SG11202100014RA (en) 2021-01-28
US11339183B2 (en) 2022-05-24
CN112867725B (zh) 2024-09-27
PL3818065T3 (pl) 2023-10-09
HUE062011T2 (hu) 2023-09-28
ZA202100192B (en) 2023-07-26
KR20210032403A (ko) 2021-03-24
ES2945561T3 (es) 2023-07-04
IL279818B2 (en) 2024-06-01
HRP20230532T1 (hr) 2023-08-04
EP3818065B1 (en) 2023-03-15
GB201811169D0 (en) 2018-08-29
CA3105566A1 (en) 2020-01-09
CN112867725A (zh) 2021-05-28
US20210340167A1 (en) 2021-11-04
JP7506653B2 (ja) 2024-06-26
MX2021000011A (es) 2021-05-12
IL279818B1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
IL246564A (en) 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases
MX2019005834A (es) Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2.
ZA202100192B (en) Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1
PH12015502780B1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
NZ751284A (en) Novel jak1 selective inhibitors and uses thereof
MX2019004070A (es) Sistema de extraccion de un sistema de circuito cerrado.
IL246579B (en) Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson's disease
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX363950B (es) Derivados de urea utiles como inhibidores de quinasa.
IL262177B (en) Pyrimidinyl Carboxamide, 5-a] compounds and their use for the treatment of medical disorders
AU2017261291A1 (en) Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
EP3452480A4 (en) SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
MX2020003400A (es) Profarmacos de dantroleno y metodos de su uso.
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
EP3344632A4 (en) Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders
NZ756936A (en) Composition and method for preventing or delaying onset of myopia comprising atropine
DK3292867T3 (da) Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion
NZ745186A (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
NZ771525A (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same